By Pharmaceutical Technology News –
Biostar Stem Cell Technology Research Institute has received the Japanese Ministry of Health, Labour and Welfare (MHLW) approval for its angel stem cell therapy for autism spectrum disorder (ASD).
Biostar is jointly operated by RBIO and Nature Cell.
To be available at Osaka Trinity Clinic, a medical centre affiliated with Biostar, individuals aged four or above diagnosed with ASD can receive the regenerative autism therapy, which utilises autologous fat-derived mesenchymal stem cells.
